Cargando…

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic

Detalles Bibliográficos
Autores principales:	Silva-Cardoso, José, Moreira, Emilia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. 2022
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411420/ https://www.ncbi.nlm.nih.gov/pubmed/36043163 http://dx.doi.org/10.1016/j.repc.2022.08.006

Ejemplares similares

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?
por: Copur, Sidar, et al.
Publicado: (2022)

Renin-angiotensin system inhibitors in hospitalised patients with COVID-19
por: Williams, Bryan
Publicado: (2021)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Renin–angiotensin system inhibitors and COVID-19: overwhelming evidence against an association
por: de Abajo, Francisco J
Publicado: (2021)

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
por: Reynolds, Harmony R., et al.
Publicado: (2020)

Renin–angiotensin system inhibition in COVID-19 patients: Friend or foe?
por: Karadağ, Bilgehan
Publicado: (2020)

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone Inhibitors and COVID-19 Infection
por: Tsampasian, Vasiliki, et al.
Publicado: (2022)

Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
por: Ferrari, Filipe, et al.
Publicado: (2021)

Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
por: Loader, Jordan, et al.
Publicado: (2021)

The Renin-Angiotensin-Aldosterone System in Metabolic Diseases and Other Pathologies
por: Ortiz, Rudy M., et al.
Publicado: (2023)

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
por: South, Andrew M., et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and COVID-19 infection
por: Alexandre, Joachim, et al.
Publicado: (2020)

Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system
por: Mandal, Amit.K.J., et al.
Publicado: (2021)

In pursuit of balance: renin–angiotensin–aldosterone system inhibitors and hyperkalaemia treatment
por: Sciatti, Edoardo, et al.
Publicado: (2023)

Relation Between Renin–Angiotensin–Aldosterone System Inhibitors and COVID-19 Severity
por: Alhaddad, Mousa J, et al.
Publicado: (2022)

Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea
por: Park, Jungchan, et al.
Publicado: (2021)

Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population
por: Sattar, Yasar, et al.
Publicado: (2021)

Should We Use Renin-Angiotensin-Aldosterone System Inhibitors Routinely in Patients With Hypertrophic Cardiomyopathy?
por: Park, Jae-Hyeong
Publicado: (2023)

Cognitive decline: mechanisms and proposed role of the renin–angiotensin–aldosterone system
por: Opie, Lionel H
Publicado: (2014)

The Yin and Yang of the Renin–Angiotensin–Aldosterone System in Acute Kidney Injury
por: Legrand, Matthieu, et al.
Publicado: (2021)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Risk of Covid-19 with renin-angiotensin-aldosterone system medications
Publicado: (2020)

Antagonizing the renin–angiotensin–aldosterone system in the era of COVID-19
por: Sarzani, Riccardo, et al.
Publicado: (2020)

COVID‐19 and renin angiotensin aldosterone system: Pathogenesis and therapy
por: Babajani, Fatemeh, et al.
Publicado: (2021)

Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients
por: Caro-Codón, Juan, et al.
Publicado: (2022)

Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity
por: Gonçalves, Jorge, et al.
Publicado: (2023)

Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19
por: Furuhashi, Masato, et al.
Publicado: (2020)

COVID-19 and the Renin-Angiotensin System
por: Malha, Line, et al.
Publicado: (2020)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
por: Kang, Si-Hyuck, et al.
Publicado: (2021)

Emergence and evolution of the renin–angiotensin–aldosterone system
por: Fournier, David, et al.
Publicado: (2012)

Beyond the Circulating Renin–Angiotensin Aldosterone System
por: De Mello, Walmor C.
Publicado: (2014)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
por: Usman, Muhammad Shariq, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tur1hjbtndjn2sjtfg1aavv6qv